Anti-TIRC7 Antibody, Non-Fucosylated (Neliximab) (CAT#: BioBet-1325ZP) Datasheet

TCIRG1

T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3

Through alternate splicing, this gene encodes two proteins with similarity to subunits of the vacuolar ATPase (V-ATPase) but the encoded proteins seem to have different functions. V-ATPase is a multisubunit enzyme that mediates acidification of eukaryotic intracellular organelles. V-ATPase dependent organelle acidification is necessary for such intracellular processes as protein sorting, zymogen activation, and receptor-mediated endocytosis. V-ATPase is comprised of a cytosolic V1 domain and a transmembrane V0 domain. Mutations in this gene are associated with infantile malignant osteopetrosis.

TCIRG1; T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3; a3; Stv1; Vph1; Atp6i; OC116; OPTB1; TIRC7; ATP6N1C; ATP6V0A3; OC-116kDa; V-type proton ATPase 116 kDa subunit a isoform 3; OC-116 kDa; V-ATPase 116-kDa; T-cell immune response cDNA 7; ATPase, H+ transporting, 116kD; V-type proton ATPase 116 kDa subunit a; osteoclastic proton pump 116 kDa subunit; specific 116-kDa vacuolar proton pump subunit; vacuolar proton translocating ATPase 116 kDa subunit A; T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 protein a

Membrane

Diseases associated with TCIRG1 include Osteopetrosis, Autosomal Recessive 1 and Autosomal Recessive Malignant Osteopetrosis.

Its related pathways are Lysosome and Synaptic vesicle cycle.

Part of the proton channel of V-ATPases (By similarity). Seems to be directly involved in T-cell activation.

1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

Neliximab

Chimeric

Human

The anti-TIRC7 antibody can be used for the treatment of an inflammatory disease, particularly rheumatoid arthritis.

Rheumatoid Arthritis

Rheumatoid Arthritis